Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2010

Content (28 Articles)

Review

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

Omar S. Din, David Dodwell, Richard J. Wakefield, Robert E. Coleman

Preclinical study

Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells

Oliver Treeck, Claus Lattrich, Anette Springwald, Olaf Ortmann

Preclinical study

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Thomas Karn, Dirk Metzler, Eugen Ruckhäberle, Lars Hanker, Regine Gätje, Christine Solbach, Andre Ahr, Marcus Schmidt, Uwe Holtrich, Manfred Kaufmann, Achim Rody

Preclinical study

Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

Madhavi Billam, Michele D. Sobolewski, Nancy E. Davidson

Preclinical study

CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors

Jinhua Xu, Dezheng Huo, Yinghua Chen, Chika Nwachukwu, Cindy Collins, Janelle Rowell, Dennis J. Slamon, Olufunmilayo I. Olopade

Preclinical study

The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype

Hany Onsy Habashy, Desmond G. Powe, Emad A. Rakha, Graham Ball, R. Douglas Macmillan, Andrew R. Green, Ian O. Ellis

Preclinical study

Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses

Mathilde Bayet-Robert, Daniel Morvan, Philippe Chollet, Chantal Barthomeuf

Clinical trial

Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer

So-Youn Jung, Hyun Yul Kim, Byung-Ho Nam, Sun Young Min, Seung Ju Lee, Chansung Park, Youngmee Kwon, Eun-A Kim, Kyoung Lan Ko, Kyung Hwan Shin, Keun Seok Lee, In Hae Park, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Jungsil Ro

Clinical trial

Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients

Niramol Chanplakorn, Pongsthorn Chanplakorn, Takashi Suzuki, Katsuhiko Ono, Monica S. M. Chan, Yasuhiro Miki, Shigetoyo Saji, Takayuki Ueno, Masakazu Toi, Hironobu Sasano

Clinical trial

Effect of air travel on lymphedema risk in women with history of breast cancer

Sharon L. Kilbreath, Leigh C. Ward, Kirstin Lane, Margaret McNeely, Elizabeth S. Dylke, Kathryn M. Refshauge, Don McKenzie, Mi-Joung Lee, Carolyn Peddle, Katie J. Battersby

Clinical trial

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

Michael Knauer, Stella Mook, Emiel J. T. Rutgers, Richard A. Bender, Michael Hauptmann, Marc J. van de Vijver, Rutger H. T. Koornstra, Jolien M. Bueno-de-Mesquita, Sabine C. Linn, Laura J. van ’t Veer

Epidemiology

The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer

Chunhui Yi, Lina Mu, Irene A. Rigault de la Longrais, Olga Sochirca, Riccardo Arisio, Herbert Yu, Aaron E. Hoffman, Yong Zhu, Dionyssios Katsaro

Epidemiology

Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer

Sophie Lauzier, Elizabeth Maunsell, Pascale Levesque, Myrto Mondor, Jean Robert, André Robidoux, Louise Provencher

Epidemiology

Urinary polyphenols and breast cancer risk: results from the Shanghai Women’s Health Study

Jianfeng Luo, Yu-Tang Gao, Wong-Ho Chow, Xiao-Ou Shu, Honglan Li, Gong Yang, Qiuyin Cai, Nathaniel Rothman, Hui Cai, Martha J. Shrubsole, Adrian A. Franke, Wei Zheng, Qi Dai

Erratum

Erratum to: Urinary polyphenols and breast cancer risk: results from the Shanghai Women’s Health Study

Jianfeng Luo, Yu-Tang Gao, Wong-Ho Chow, Xiao-Ou Shu, Honglan Li, Gong Yang, Qiuyin Cai, Nathaniel Rothman, Hui Cai, Martha J. Shrubsole, Adrian A. Franke, Wei Zheng, Qi Dai

Epidemiology

Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis

Zheng Hu, Xiang Li, Rong Yuan, Brian Z. Ring, Li Su

Epidemiology

Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

Belinda E. Kiely, Mark A. Jenkins, Joanne M. McKinley, Michael L. Friedlander, Prue Weideman, Roger L. Milne, Sue-Anne McLachlan, John L. Hopper, Kelly-Anne Phillips

Erratum

Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

Belinda E. Kiely, Mark A. Jenkins, Joanne M. McKinley, Michael L. Friedlander, Prue Weideman, Roger L. Milne, Sue-Anne McLachlan, John L. Hopper, Kelly-Anne Phillips

Epidemiology

Common genetic variations in the LEP and LEPR genes, obesity and breast cancer incidence and survival

Rebecca J. Cleveland, Marilie D. Gammon, Chang-Min Long, Mia M. Gaudet, Sybil M. Eng, Susan L. Teitelbaum, Alfred I. Neugut, Regina M. Santella

Epidemiology

Patterns of relapse in breast cancer: changes over time

Rinat Yerushalmi, Ryan Woods, Hagen Kennecke, Caroline Speers, Meg Knowling, Karen Gelmon

Brief Report

Breast cancer-derived M543V mutation in helix 12 of estrogen receptor α inverts response to estrogen and SERMs

Mark Nichols, Peng Cheng, Yue Liu, Beatriz Kanterewicz, Pamela A. Hershberger, Kenneth S. McCarty Jr

Brief Report

Telomere length in blood cells and breast cancer risk: investigations in two case–control studies

Yun-Ling Zheng, Christine Ambrosone, Celia Byrne, Warren Davis, Mary Nesline, Susan E. McCann

Brief Report

Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome

Uffe Birk Jensen, Lone Sunde, Susanne Timshel, Britta Halvarsson, Anja Nissen, Inge Bernstein, Mef Nilbert

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine